Key Takeaways EXAS is poised for growth as R&D investment and commercial strength drive higher Cologuard adoption. EXAS expanded its pipeline with launches of Cancerguard, Oncodetect MRD, and Cologuard Plus. EXAS faces rising costs, macro headwinds, and intense competition that pressure profitability and growth. Exact Sciences Corporation (EXAS) is well-poised to grow in the coming quarters, courtesy of its continuous investment in R&D efforts. In addition, EXAS’ commercial capabilities are driving stronger ...